AlphAIAlphAI — Financial news for AI agents
investing.comOCT 52 min read$CLYM

Raymond James reiterates Strong Buy on Climb Bio stock ahead of data

Raymond James maintained a Strong Buy rating and $34.00 price target for Climb Bio (NASDAQ:CLYM) after Phase 2 budoprutug data abstract release. The stock is up 453% over a year, trading at $10.94. Analysts' targets range from $18 to $40, with a consensus Strong Buy. Initial data shows safety and B cell depletion, with a full presentation expected on October 24. Recent Phase 1 trial results for CLYM116 also led to multiple analyst upgrades and higher price targets.

Original reporting
investing.com
Published Oct 5, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 10:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLYM
Bullish
high confidence
Mentioned
$CLYM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CLYMBullishHigh
01

Why it matters

The abstract indicates strong target engagement and safety, which may lift the stock toward the new $34 price target.

02

Market read

First public Phase 2 data release for CLYM, a catalyst likely to move the stock in the short term.

03

What to watch

Potential safety concerns from the reported neutropenia event and the small patient cohort size.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Raymond James reaffirmed its Strong Buy rating on Climb Bio (NASDAQ:CLYM) following an abstract release of Phase 2 budoprutug data presented at ASN Kidney Week.

Company-level read

Ticker impact

$CLYMBullishHigh confidence
Context

Raymond James reiterated a Strong Buy and $34 price target after the release of a Phase 2 abstract showing >90% B‑cell depletion in 5 patients.

Expected impact

upward pressure as investors price in supportive early‑stage data

Evidence & confidence

The abstract is the first public disclosure of Phase 2 results, a material catalyst for a biotech with no prior data at this stage.

Market effects

Sector

Boosts sentiment for the broader nephrology‑focused biotech sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minor global impact, primarily relevant to specialty pharma investors.

Counterpoint

What could challenge this read

If the full Phase 2 data later shows limited efficacy, the current rally could reverse.

Key entities

  • company
    Climb Bio

    Biotech developing budoprutug for membranous nephropathy.

  • analyst_firm
    Raymond James

    Equity research firm reiterating Strong Buy on CLYM.

Read at source← All news

Related articles

OCT 23
$CLYMMedAI 8/10

Climb Bio Reports CLYM116 Phase 1 Data Supporting 12-Week Dosing

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

tradingview.com1 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

SEC EDGAR 8-K2 min
OCT 23
$CLYMHighAI 8/10

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.

markets.businessinsider.com3 min
OCT 20
$CLYMHigh

Why is Climb Bio stock surging today?

Climb Bio Inc. (CLYM) rose 10.9% after Deutsche Bank initiated coverage with a Buy rating and $28.00 target, citing its autoimmune drug pipeline. The bank noted recent valuation compression reflected sector-wide selloff, not company-specific issues. Multiple analysts maintain bullish ratings with targets up to $40, citing positive clinical data. Broader market gains and biotech sector stabilization also supported the move.

investing.com2 min
OCT 20
$CLYMHigh

Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

Climb Bio (CLYM) shares rose 10% after Deutsche Bank initiated coverage with a Buy rating and $28 price target, citing its autoimmune pipeline and attractive valuation. Analyst David Hoang highlighted CLYM116 as a key growth driver and noted upcoming clinical updates as catalysts. The firm sees significant commercial potential in the company's pipeline, including budoprutug for multiple B cell-mediated disorders.

investing.com2 min